CohBar: Lowest in over a year after suspending liver drug study

CohBar

05/11/2018 16:31

** Shares of drug developer  CWBR.O  plunge as much as 40.4
pct to $2.55, their lowest since late September 2017 
    ** Says early stage study of CB4211, its lead drug to treat
non-alcoholic steatohepatitis (NASH) and obesity, has been
temporarily suspended  urn:newsml:reuters.com:*:nGNX6cfHqR
    ** In NASH patients, excess fat is stored in the liver,
which becomes inflamed and poses the risk of scarring and
cancer; analysts estimate the market in treating NASH to be
worth as much as $30 bln
    ** Currently, there are no FDA-approved drug to treat NASH
patients in the United States
    ** Viking Therapeutics Inc  VKTX.O  and Madrigal
Pharmaceuticals Inc  MDGL.O  are few other companies developing
drugs to treat the liver disease  urn:newsml:reuters.com:*:nL3N1W44BJ
    ** CWBR shares are now down 32.4 pct for the year

 (Reporting by Shreyashi Sanyal in Bengaluru)
 ((RM: Shreyashi.Sanyal.thomsonreuters.com@reuters.net))